Belgian drugmaker UCB, BoneBot’s developer, said licensing it out to ImageBiopsy could see it brought into clinical practice by 2023, according to the report.
The AI focuses on identifying small vertebral compression fractures and distinguishing them from other problems such as vertebral degeneration. It will be integrated into ImageBiopsy’s existing AI-based platform, according to pharmaphorum.
